Journal
MOLECULAR PHARMACOLOGY
Volume 58, Issue 4, Pages 852-858Publisher
AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
DOI: 10.1124/mol.58.4.852
Keywords
-
Categories
Funding
- NIEHS NIH HHS [ES04917, ES000834, ES09106] Funding Source: Medline
Ask authors/readers for more resources
We previously demonstrated differential interactions of the methoxychlor metabolite 2,2- bis(p-hydroxyphenyl)-1,1,1-trichloroethane(HPTE) with estrogen receptor alpha (ER alpha), ER beta, and the androgen receptor (AR). In this study, we characterize the ER alpha, ER beta, and AR activity of structurally related methoxychlor metabolites. Human hepatoma cells (HepG2) were transiently transfected with human ER alpha, ER beta, and AR plus an appropriate steroid-responsive luciferase reporter vector. After transfection, cells were treated with various concentrations of HPTE or structurally related compounds in the presence (for detecting antagonism) and absence (for detecting agonism) of 17 beta-estradiol and dihydrotestosterone. The monohydroxy analog of methoxychlor, as well as monohydroxy and dihydroxy analogs of 2,2- bis(p-hydroxyphenyl)-1,1-dichloroethylene, had ER alpha agonist activity and ER beta and AR antagonist activity similar to HPTE. The trihydroxy metabolite of methoxychlor displayed only weak ER alpha agonist activity and did not alter ER beta or AR activities. Replacement of the trichloroethane or dichloroethylene group with a methyl group resulted in a compound with ER alpha and ER beta agonist activity that retained antiandrogenic activities. This study identifies some of the structural requirements for ER alpha and ER beta activity and demonstrates the complexity involved in determining the mechanism of action of endocrine-active chemicals that simultaneously act as agonists or antagonists through one or more hormone receptors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available